Gilead Sciences’ Earnings Miss Forecasts as ACA Drives Higher Costs

Shares of Gilead Sciences (GILD) have dropped in after-hours trading following the release of disappointing earnings driven primarily by Affordable Care Act-related costs. Paul Sakuma Gilead reported a profit of $1.84 a share not including special items, missing forecasts for $1.92 a share, on sales of $6.04 billion, topping estimates for $5.98 billion. Those aforementioned [...]